Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$4.38
Change (%) Stock is Down 0.04 (0.90%)
Volume132,979
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
07/11/18Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health
Findings from Aarhus University Hospital and the University of Copenhagen Suggest Further Studies on NIAGEN® Should Focus on Therapeutic Potential for Liver Health IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus University Hospital, we... 
Printer Friendly Version
07/09/18TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the 2018 Healthy Aging Summit
Participation at two mid-July events will target healthcare practitioners IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its flagship consumer product to help improve the aging process, TRU NIAGEN®, at the American Association of Naturopathic Physicians Annual Convention as well as the 2018 Healthy Aging Summit. The sole active ... 
Printer Friendly Version
06/25/18ChromaDex added to membership of US small-cap Russell 2000® Index
IRVINE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 25, as part of the 2018 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one... 
Printer Friendly Version
What's New
Download DocumentationJuly 2018 Investor Presentation
Download DocumentationQ1 2018 Earnings Presentation
Download Documentation2018 Q1 Quarterly Report on Form 10Q
Download Documentation2018 Proxy Statement
Download Documentation2017 Annual Report on Form 10K
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.